170 related articles for article (PubMed ID: 1752346)
1. Variation of insulin absorption during subcutaneous and peritoneal infusion in insulin-dependent diabetic patients with unsatisfactory long-term glycaemic response to continuous subcutaneous insulin infusion.
Wredling R; Liu D; Lins PE; Adamson U
Diabete Metab; 1991; 17(5):456-9. PubMed ID: 1752346
[TBL] [Abstract][Full Text] [Related]
2. Insulin kinetics in type I diabetic patients treated by continuous intraperitoneal insulin infusion: influence of anti-insulin antibodies.
Lassmann-Vague V; Belicar P; Alessis C; Raccah D; Vialettes B; Vague P
Diabet Med; 1996 Dec; 13(12):1051-5. PubMed ID: 8973887
[TBL] [Abstract][Full Text] [Related]
3. Continuous intraperitoneal insulin infusion partly restores the glucagon response to hypoglycaemia in type 1 diabetic patients.
Oskarsson PR; Lins PE; Backman L; Adamson UC
Diabetes Metab; 2000 Apr; 26(2):118-24. PubMed ID: 10804326
[TBL] [Abstract][Full Text] [Related]
4. Near normalization of metabolism of IDDM: comparison of continuous subcutaneous (CSII) versus intraperitoneal (CIPII) insulin delivery.
Gooch BR; Abumrad NN; Robinson RP; Crofford OB
Horm Metab Res; 1984 Dec; 16 Suppl 1():190-4. PubMed ID: 6398261
[TBL] [Abstract][Full Text] [Related]
5. Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion.
Raz I; Weiss R; Yegorchikov Y; Bitton G; Nagar R; Pesach B
Clin Ther; 2009 May; 31(5):980-7. PubMed ID: 19539098
[TBL] [Abstract][Full Text] [Related]
6. Benefits of continuous subcutaneous insulin infusion in type 1 diabetes previously treated with multiple daily injections with once-daily glargine and pre-meal analogues.
Torres I; Ortego J; Valencia I; García-Palacios MV; Aguilar-Diosdado M
Exp Clin Endocrinol Diabetes; 2009 Sep; 117(8):378-85. PubMed ID: 19629931
[TBL] [Abstract][Full Text] [Related]
7. In Type 1 diabetic patients with good glycaemic control, blood glucose variability is lower during continuous subcutaneous insulin infusion than during multiple daily injections with insulin glargine.
Bruttomesso D; Crazzolara D; Maran A; Costa S; Dal Pos M; Girelli A; Lepore G; Aragona M; Iori E; Valentini U; Del Prato S; Tiengo A; Buhr A; Trevisan R; Baritussio A
Diabet Med; 2008 Mar; 25(3):326-32. PubMed ID: 18307459
[TBL] [Abstract][Full Text] [Related]
8. Postprandial insulin profiles with implantable pump therapy may explain decreased frequency of severe hypoglycemia, compared with intensive subcutaneous regimens, in insulin-dependent diabetes mellitus patients.
Nathan DM; Dunn FL; Bruch J; McKitrick C; Larkin M; Haggan C; Lavin-Tompkins J; Norman D; Rogers D; Simon D
Am J Med; 1996 Apr; 100(4):412-7. PubMed ID: 8610727
[TBL] [Abstract][Full Text] [Related]
9. Subcutaneous absorption of insulin in insulin-dependent diabetic patients. Influence of species, physico-chemical properties of insulin and physiological factors.
Hildebrandt P
Dan Med Bull; 1991 Aug; 38(4):337-46. PubMed ID: 1914533
[TBL] [Abstract][Full Text] [Related]
10. Pre- and postprandial hyperinsulinemia during insulin pump treatment; role of the subcutaneous bolus and basal infusion.
Olsson PO; Jorfeldt L; Arnqvist H; Gerhardsson P
Diabetes Res; 1991 Feb; 16(2):55-61. PubMed ID: 1817806
[TBL] [Abstract][Full Text] [Related]
11. Subcutaneous insulin substitution in insulin-dependent diabetes mellitus. Pharmacokinetic and pharmacodynamic studies.
Olsson PO
Acta Med Scand Suppl; 1987; 718():1-78. PubMed ID: 3321929
[TBL] [Abstract][Full Text] [Related]
12. A 2-way cross-over, open-labeled trial to compare efficacy and safety of insulin Aspart and Novolin R delivered with CSII in 21 Chinese diabetic patients.
Bi YF; Zhao LB; Li XY; Wang WQ; Sun SY; Chen YH; Hong J; Su TW; Liu JM; Ning G
Chin Med J (Engl); 2007 Oct; 120(19):1700-3. PubMed ID: 17935674
[TBL] [Abstract][Full Text] [Related]
13. Intraperitoneal insulin delivery to patients with type 1 diabetes results in higher serum IGF-I bioactivity than continuous subcutaneous insulin infusion.
Hedman CA; Frystyk J; Lindström T; Oskarsson P; Arnqvist HJ
Clin Endocrinol (Oxf); 2014 Jul; 81(1):58-62. PubMed ID: 23865977
[TBL] [Abstract][Full Text] [Related]
14. Insulin-mediated glucose disposal in type 1 (insulin-dependent) diabetic subjects treated by continuous subcutaneous or intraperitoneal insulin fusion.
Beylot M; Khalfallah Y; Laville M; Sautot G; Dechaud H; Serusclat P; Berthezene F; Riou JP; Mornex R
Diabete Metab; 1987; 13(4):450-6. PubMed ID: 3315766
[TBL] [Abstract][Full Text] [Related]
15. Long-term benefits of continuous subcutaneous insulin infusion in children with Type 1 diabetes: a 4-year follow-up.
Sulli N; Shashaj B
Diabet Med; 2006 Aug; 23(8):900-6. PubMed ID: 16911629
[TBL] [Abstract][Full Text] [Related]
16. Impaired endothelial antithrombotic activity following short-term interruption of continuous subcutaneous insulin infusion in type 1 diabetic patients.
Iorio A; Federici MO; Mourvaki E; Ferolla P; Piroddi M; Stabile A; Timi A; Celleno R; Benedetti MM
Thromb Haemost; 2007 Sep; 98(3):635-41. PubMed ID: 17849053
[TBL] [Abstract][Full Text] [Related]
17. [Assessment of metabolic control and safety of continuous subcutaneous insulin infusion in prepubertal children with type 1 diabetes mellitus].
Minkina-Pedras M; Jarosz-Chobot P; Małecka-Tendera E; Deja G
Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2005; 11(3):171-6. PubMed ID: 16232370
[TBL] [Abstract][Full Text] [Related]
18. Free insulin profiles during intensive treatment with biosynthetic human insulin.
Olsson PO; Arnqvist HJ; Von Schenck HV
Diabete Metab; 1988; 14(3):253-8. PubMed ID: 3044863
[TBL] [Abstract][Full Text] [Related]
19. Glucose profiles in a type 1 diabetic patient successively treated with CSII using regular insulin, lispro and an implantable insulin pump.
Catargi B; Breilh D; Roger P; Tabarin A
Diabetes Metab; 2000 May; 26(3):210-4. PubMed ID: 10880895
[TBL] [Abstract][Full Text] [Related]
20. [Continuous subcutaneous insulin infusion brings about normal blood sugar in type I diabetes mellitus despite relaxing of diet instructions].
Sonnenberg GE; Chantelau E; Altenähr H; Berger M; Berchtold P
Schweiz Med Wochenschr; 1982 Jan; 112(3):83-5. PubMed ID: 7036337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
